These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22383427)

  • 1. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
    Oh SJ; Erb HH; Hobisch A; Santer FR; Culig Z
    Endocr Relat Cancer; 2012 Jun; 19(3):305-19. PubMed ID: 22383427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
    Kharaziha P; Rodriguez P; Li Q; Rundqvist H; Björklund AC; Augsten M; Ullén A; Egevad L; Wiklund P; Nilsson S; Kroemer G; Grander D; Panaretakis T
    Cell Death Dis; 2012 Jan; 3(1):e262. PubMed ID: 22278289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
    Huang R; Chen XQ; Huang Y; Chen N; Zeng H
    Asian J Androl; 2010 Jul; 12(4):527-34. PubMed ID: 20473320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
    Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
    Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
    Yang F; Van Meter TE; Buettner R; Hedvat M; Liang W; Kowolik CM; Mepani N; Mirosevich J; Nam S; Chen MY; Tye G; Kirschbaum M; Jove R
    Mol Cancer Ther; 2008 Nov; 7(11):3519-26. PubMed ID: 19001435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
    Yang F; Brown C; Buettner R; Hedvat M; Starr R; Scuto A; Schroeder A; Jensen M; Jove R
    Mol Cancer Ther; 2010 Apr; 9(4):953-62. PubMed ID: 20371721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
    Katz SI; Zhou L; Chao G; Smith CD; Ferrara T; Wang W; Dicker DT; El-Deiry WS
    Cancer Biol Ther; 2009 Dec; 8(24):2406-16. PubMed ID: 20038816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
    Roy Choudhury S; Karmakar S; Banik NL; Ray SK
    Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
    Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
    J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
    Ambrosini G; Cheema HS; Seelman S; Teed A; Sambol EB; Singer S; Schwartz GK
    Mol Cancer Ther; 2008 Apr; 7(4):890-6. PubMed ID: 18413802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Mol Cancer Ther; 2010 Mar; 9(3):742-50. PubMed ID: 20197401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway.
    Divakar S; Saravanan K; Karthikeyan P; Elancheran R; Kabilan S; Balasubramanian KK; Devi R; Kotoky J; Ramanathan M
    Chem Biol Interact; 2017 Sep; 275():22-34. PubMed ID: 28757136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
    Delgado JS; Mustafi R; Yee J; Cerda S; Chumsangsri A; Dougherty U; Lichtenstein L; Fichera A; Bissonnette M
    Dig Dis Sci; 2008 Dec; 53(12):3055-64. PubMed ID: 18512153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
    Niessner H; Beck D; Sinnberg T; Lasithiotakis K; Maczey E; Gogel J; Venturelli S; Berger A; Mauthe M; Toulany M; Flaherty K; Schaller M; Schadendorf D; Proikas-Cezanne T; Schittek B; Garbe C; Kulms D; Meier F
    J Invest Dermatol; 2011 Feb; 131(2):468-79. PubMed ID: 20944654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hydroxytyrosol Induces Apoptosis and Cell Cycle Arrest and Suppresses Multiple Oncogenic Signaling Pathways in Prostate Cancer Cells.
    Zubair H; Bhardwaj A; Ahmad A; Srivastava SK; Khan MA; Patel GK; Singh S; Singh AP
    Nutr Cancer; 2017; 69(6):932-942. PubMed ID: 28718667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
    Pignochino Y; Grignani G; Cavalloni G; Motta M; Tapparo M; Bruno S; Bottos A; Gammaitoni L; Migliardi G; Camussi G; Alberghini M; Torchio B; Ferrari S; Bussolino F; Fagioli F; Picci P; Aglietta M
    Mol Cancer; 2009 Dec; 8():118. PubMed ID: 20003259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
    Rahmani M; Davis EM; Bauer C; Dent P; Grant S
    J Biol Chem; 2005 Oct; 280(42):35217-27. PubMed ID: 16109713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.